Fredun Pharmaceuticals Limited (BOM:539730)
India flag India · Delayed Price · Currency is INR
1,577.60
+43.45 (2.83%)
At close: Mar 9, 2026

Fredun Pharmaceuticals Ratios and Metrics

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 2020 - 2016
Market Capitalization
7,4493,1423,3713,5724,0571,849
Upgrade
Market Cap Growth
128.34%-6.80%-5.63%-11.97%119.38%297.73%
Upgrade
Enterprise Value
9,0724,4963,9934,4194,5112,181
Upgrade
Last Close Price
1577.60668.17716.23775.47912.61461.51
Upgrade
PE Ratio
22.4115.9221.5833.0564.0491.80
Upgrade
PS Ratio
1.260.690.971.301.811.38
Upgrade
PB Ratio
4.742.222.783.715.964.29
Upgrade
P/TBV Ratio
4.752.232.793.725.974.30
Upgrade
P/OCF Ratio
-----1088.52
Upgrade
EV/Sales Ratio
1.530.991.151.612.011.63
Upgrade
EV/EBITDA Ratio
11.258.3810.5015.8232.5123.72
Upgrade
EV/EBIT Ratio
12.129.2311.6417.5638.4230.24
Upgrade
Debt / Equity Ratio
1.091.190.870.900.891.06
Upgrade
Debt / EBITDA Ratio
2.123.142.773.104.374.99
Upgrade
Net Debt / Equity Ratio
1.031.150.850.860.861.04
Upgrade
Net Debt / EBITDA Ratio
2.013.032.722.984.224.86
Upgrade
Net Debt / FCF Ratio
--4.62-12.80-3.48-8.78-36.69
Upgrade
Asset Turnover
-1.141.231.241.290.88
Upgrade
Inventory Turnover
-1.691.702.233.231.81
Upgrade
Quick Ratio
-0.560.400.271.250.49
Upgrade
Current Ratio
-1.301.541.552.071.51
Upgrade
Return on Equity (ROE)
-15.02%14.34%13.14%11.40%4.78%
Upgrade
Return on Assets (ROA)
-7.66%7.59%7.08%4.21%2.97%
Upgrade
Return on Invested Capital (ROIC)
17.79%13.23%12.35%10.15%8.07%5.47%
Upgrade
Return on Capital Employed (ROCE)
-30.60%24.40%21.40%10.40%9.60%
Upgrade
Earnings Yield
4.39%6.28%4.63%3.03%1.56%1.09%
Upgrade
FCF Yield
--11.20%-2.40%-6.69%-1.64%-0.66%
Upgrade
Dividend Yield
0.04%0.10%0.10%0.09%0.08%0.15%
Upgrade
Buyback Yield / Dilution
0.36%--3.66%-7.85%-4.06%-0.01%
Upgrade
Total Shareholder Return
0.40%0.10%-3.56%-7.76%-3.98%0.14%
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.